Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failureComparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial COMET: randomised controlled trial.

  • Furberg, Curt D MD, PhD (commentator)
  • Psaty, Bruce M MD, PhD (commentator)
  • Poole-Wilson, PA
  • Swedberg, K
  • Cleland, JG
  • et al,

  • 1Wake Forest University School of Medicine Winston-Salem, North Carolina, USA

    2University of Washington Seattle, Washington, USA

Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7–13.Poole-WilsonPASwedbergKClelandJGet alComparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial COMET: randomised controlled trial.Lancet20033627-13Q In patients with chronic heart failure (CHF), what is the comparative effectiveness of carvedilol and metoprolol tartrate on morbidity and mortality?

Abstract and commentary also appear in ACP Journal Club.

For correspondence: Professor P A Poole-Wilson, National Heart and Lung Institute, London, UK. [email protected]

Sources of funding: F Hoffman La Roche and GlaxoSmithKline.

Evidence Based Medicine 9(1):p 14, February 2004.
Copyright © 2004 BMJ Publishing Group Ltd